Pharmaceuticals Australia

Australia Influenza Antivirals Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Influenza Antivirals Market Industry Trends and Forecast to 2034: Segmented by (Drug, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $16.1 Mn Placeholder estimate
Estimate 2025 $16.9 Mn 1.3% of the global market
Projected 2034 $26.4 Mn 56.5% Adds $9.5 Mn over 9 forecast years
CAGR 2025–2034 5.1% Faster than 4% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.3% of the global market.
  • In APAC, the largest is China at $107.9 Mn.
  • Fastest growing: India at 6.9% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$9.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Influenza Antivirals Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $16.1 Mn — —
2025 (base) $16.9 Mn +$0.8 Mn —
2026 (forecast) $17.8 Mn +$0.9 Mn +5.1%
2027 (forecast) $18.7 Mn +$0.9 Mn +10.5%
2028 (forecast) $19.6 Mn +$1.0 Mn +16.1%
2029 (forecast) $20.6 Mn +$1.0 Mn +22%
2030 (forecast) $21.7 Mn +$1.1 Mn +28.2%
2031 (forecast) $22.8 Mn +$1.1 Mn +34.8%
2032 (forecast) $23.9 Mn +$1.2 Mn +41.7%
2033 (forecast) $25.2 Mn +$1.2 Mn +48.9%
2034 (forecast) $26.4 Mn +$1.3 Mn +56.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Influenza Antivirals Market Analysis at a glance
Market size, 2025$16.9 Mn placeholder estimate
Forecast, 2034$26.4 Mn placeholder estimate
Growth (CAGR), 2025–20345.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, buyer and end user (see all)
Key playersRoche, Shionogi, GSK PLC, BioCryst Pharmaceuticals, Cipla Inc. (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials11 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Influenza Antivirals Market Analysis Executive Summary

Influenza antivirals treat flu and shorten illness if started early, and are stockpiled for pandemics.

Key segments of the influenza Antivirals market include drug (Oseltamivir, Baloxavir and Zanamivir) and buyer (Retail, Hospitals and Government Stockpiles).

Bar chart: Australia Influenza Antivirals market size, 2024–2034, placeholder estimates. $16.1 Mn in 2024, $16.9 Mn in 2025 and $26.4 Mn in 2034, 5.1% CAGR.
Australia Influenza Antivirals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Influenza Antivirals Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the influenza Antivirals market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the influenza Antivirals market.

Competitive Landscape for Influenza Antivirals Market in Australia

The influenza Antivirals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Influenza Antivirals Market in Australia

Influenza Antivirals in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 11 studies on Influenza Antivirals that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for influenza Antivirals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Influenza Antivirals right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Influenza Antivirals in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Influenza Antivirals market in Australia?
Placeholder estimate: about $16.9 Mn in 2025, rising to about $26.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Influenza Antivirals market in Australia growing?
Placeholder estimate: about 5.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Influenza Antivirals market report cover?
The report splits the market by drug (Oseltamivir, Baloxavir, Zanamivir, Peramivir), buyer (Retail, Hospitals, Government Stockpiles) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Influenza Antivirals market?
Key players include Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals and Cipla Inc..
What is driving the Influenza Antivirals market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
Who regulates Influenza Antivirals in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Influenza Antivirals are running in Australia?
11 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Influenza Antivirals?
PubMed lists 47 papers on Influenza Antivirals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on influenza and infectious diseases

See the topic